EP02.01-001 Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients

Abstract

Lung cancer is the worldwide leading cause of cancer-related death. Thoracic Surgical lung cancer patients often possess smoking associated comorbidities including coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD). The Charlson Comorbidity Index (CCI) is currently used to quantify wellbeing and risk of postoperative complications. An objective biomarker surrogate for wellbeing such as circulating cell-free DNA (cfDNA) could aide in perioperative risk estimation and monitoring.